Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...

Penpulimab-kcqx, a humanized immunoglobulin G1 monoclonal antibody, blocks the interaction between the programmed death 1 receptor on T-cells and programmed death ligand 1 and 2 on tumor cells.

Researchers examined the affect of surgical interval duration on the prognosis of patients with cutaneous melanoma.

Chemotherapy can increase mutation burden and change the cell population structure of normal blood, which contributes to long-term adverse effects such as second malignancies and infertility, ...